Nilesh Kumar Sharma* Pages 170 - 171 ( 2 )
In recent, curiosity is at the forefront to understand the complexity of cancer driven by genetic, molecular and epigenetic programming due to life style, environmental pressure and metabolite adaptations. On the other hand, complex and heterogeneous nature of cancer is linked to the metabolic and molecular landscape of diabetic complications. This Letter to editor connects the dots and highlights the need to view cancer beyond the mirror of genetic and epigenetic aberration as metabolic disturbances. In this commentary, the author highlights the major contributions from two elegant papers from Cha et al. (2018) and Wu et al. (2018) by delineating molecular pathways that lead to the potential use of anti-diabetic drug metformin and other potential repurposing drugs towards cancer therapeutics.
Aging, diabetes, tumor, cancer, epigenetic programming, metabolite.
Cancer and Translational Research Lab, Dr. D.Y. Patil Biotechnology & Bioinformatics Institute, Dr. D.Y. Patil Vidyapeeth, Pune, Maharashtra, 411033